Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Repligen's EV/EBITDA was 62.3× on Nov 11, 2026, against 113.9× a year earlier. Over the last 5 years it ranged from 28.7× to 236.6×, with a median of 61.7×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 62.3× | −46.4 |
| 2025 | Dec 31, 2025 | 108.7× | +17.5 |
| 2024 | Dec 31, 2024 | 91.2× | +29.5 |
| 2023 | Dec 29, 2023 | 61.7× | +27.9 |
| 2022 | Dec 30, 2022 | 33.8× | −43.1 |
| 2021 | Dec 31, 2021 | 77.0× | −36.5 |
| 2020 | Dec 31, 2020 | 113.5× | +38.0 |
| 2019 | Dec 31, 2019 | 75.5× | +18.6 |
| 2018 | Dec 31, 2018 | 56.9× | −9.1 |
| 2017 | Dec 29, 2017 | 66.0× | +20.6 |
| 2016 | Dec 30, 2016 | 45.4× | −6.9 |
| 2015 | Dec 31, 2015 | 52.3× | +21.1 |
| 2014 | Dec 31, 2014 | 31.2× | −254.8 |
| 2013 | Dec 31, 2013 | 286.0× | +175.3 |
| 2012 | Dec 31, 2012 | 110.6× | +66.6 |
| 2011 | Dec 30, 2011 | 44.1× | – |
See a number that looks wrong?